Antidepressant Nonadherence in Routine Clinical Settings Determined From Discarded Blood Samples

Ashlee M. Roberson, BA; Victor M. Castro, MS; Andrew Cagan, BA; and Roy H. Perlis, MD, MSc

Published: March 23, 2016

Article Abstract

Objective: Antidepressant nonadherence is common and represents a potentially modifiable risk factor for treatment nonresponse. We used a novel approach based on discarded blood samples from routine clinical blood draws to assess treatment nonadherence in a general clinical population.

Method: Individuals diagnosed with or without major depressive disorder (using ICD-9) and prescribed sertraline, citalopram, bupropion, or venlafaxine in January 2014 were identified by querying the electronic health record of 2 academic medical centers. Discarded blood samples from routine blood draws for 109 individuals within 14-90 days of treatment initiation were anonymized and then assessed for detectable serum antidepressant levels.

Results: Overall, 17% of samples lacked detectable levels of the index antidepressant. Individuals with public versus private insurance were more likely to have undetectable antidepressant levels (χ21 = 5.07, P = .02) as were those receiving shorter-term (< 90 days) prescriptions (χ21 = 4.03, P = .05).

Conclusions: In general, electronic prescribing data provided a reasonable proxy for actual antidepressant use. Additionally, up to 1 in 5 individuals prescribed an antidepressant may not be adherent, suggesting the need for further efforts to reduce treatment nonadherence.

Volume: 77

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Insights

LAI Antipsychotics in Schizophrenia: Long-term Outcomes of Early Use

Using data from the...

Read More...